Progress of apatinib in treatment of lung cancer
10.3760/cma.j.cn115355-20210602-00243
- VernacularTitle:阿帕替尼治疗肺癌的研究进展
- Author:
Xuewei LIU
1
;
Hongfeng ZHOU
Author Information
1. 哈尔滨医科大学附属肿瘤医院头颈泌尿生殖内科，哈尔滨 150081
- Keywords:
Lung neoplasms;
Apatinib;
Adverse reactions;
Prognosis
- From:
Cancer Research and Clinic
2022;34(7):551-554
- CountryChina
- Language:Chinese
-
Abstract:
Lung cancer is the most common malignant tumor. As the first-generation oral small-molecule tyrosine kinase inhibitor independently developed in China, apatinib can block many kinds of signaling pathways with high selectivity, and play an anti-tumor effect by inhibiting tumor angiogenesis, and the adverse reactions are controllable. More and more studies have shown that apatinib can be used for the second-line and beyond treatment of patients with advanced non-small cell lung cancer. This article reviews the mechanisms and clinical studies of apatinib in treatment of lung cancer.
